- Poster presentation
- Open access
- Published:
Estimation of efficacy early selective LPS sorption in patients with septic shock
Critical Care volume 16, Article number: P75 (2012)
Background
Recent improvements in the treatment of severe Gram-negative sepsis have not resulted in a substantial decrease in mortality. LPS, originating from Gram-negative bacteria, is a major mediator in the development of septic shock [1]. Decreasing the load of LPS in these patients may be beneficial for these patients. The Alteco LPS Adsorber® selectively binds the lipid A moiety of LPS. Positive effects of the adsorber have been reported [2–4].
Methods
Nineteen patients with Gram-negative sepsis were treated with the Alteco LPS Adsorber®, in addition to standard therapy according to SSC Guidelines 2008. All patients needed inotropic support and mechanical lung ventilation. The mean APACHE II score at the start of treatment was 25.9 ± 1.8. The time to initiating the perfusion varied between 1.7 and 8.6 hours after the diagnosis of septic shock. The treatment lasted 120 minutes and was repeated after 24 hours. The SOFA score, oxygenation index (PaO2/FiO2) and the dose of dopamine was noted before and 48 hours after the treatment.
Results
At baseline, the severity of MODS was SOFA score 9.2 ± 2.8. At 48 hours the mean score SOFA was 4.3 ± 2.7, at the expense of an increase in the index of oxygenation from 128.6 ± 36.2 to 253.5 ± 44.8; and a decrease in doses of inotropic support (dopamine) from 17.1 ± 1.8 mkg/kg/minute to 4.2 ± 1.8 mkg/kg/minute. We found an inverse correlation between the time to initiate treatment with the adsorbtion and the decrease in SOFA score (R = -0.69; P < 0.1) (Figure 1). The degree of reduction of MODS depending on time of initiation of therapy is shown in Figure 2. The 28-day mortality was 26.3% in this patient group. There were no adverse events related to use of the adsorber.
Conclusion
Since LPS is a major mediator in Gram-negative sepsis, there is a rationale for rapid removal of LPS from patients with sepsis. Early initiation of LPS adsorption is most effective for reducing the signs of MODS. Our experiences with the use of Alteco LPS Adsorber® are promising as shown by our data above and are in support of previous findings [2–4]. The results are limited by the lack of controls; however, we believe that further randomized controlled clinical studies using this therapy are warranted, more so in view of the fact that no specific treatment against septic shock is available.
References
Marshall JC, et al.: Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J Infect Dis 2004, 190: 527-534. 10.1086/422254
Kulabukhov V: Use of novel technique for adsorption of lipopolysaccharide in the combined treatment of patients with severe organ negative sepsis [abstract 78]. Sepsis 2008; An International Sepsis Symposium; Paris. France
Kulabukhov V, Chizhov A, Kleuzovich A, Kudryavtsev A: Clinical effects of adsorption of lipopolysaccharide in the treatment of Gram-negative severe sepsis. Crit Care 2010, 14(Suppl 2):P28. 10.1186/cc9131
Ala-Kokko TI, Laurila J, Koskenkari J: A new endotoxin adsorber in septic shock: observational case series. Blood Purif 2011, 32: 303-309. 10.1159/000330323
Author information
Authors and Affiliations
Rights and permissions
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Kulabukhov, V., Kudryavtsev, A. & Chizhov, A. Estimation of efficacy early selective LPS sorption in patients with septic shock. Crit Care 16 (Suppl 3), P75 (2012). https://doi.org/10.1186/cc11762
Published:
DOI: https://doi.org/10.1186/cc11762